Pomalidomide

• CAT Number: A000692
• CAS Number: 19171-19-8
• Molecular Formula: C13H11N3O4
• Molecular Weight: 273.24
• Purity: ≥95%
• Synonyms: 19171-19-8; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; Actimid; Pomalyst; CC-4047
• Target: Apoptosis
• Solubility: >7.5mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
• InChI: 1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
• InChIKey: UVSMNLNDYGZFPF-UHFFFAOYSA-N
• SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

Pomalidomide (Cat No.: A000692) is an immunomodulatory drug (IMiD) used primarily in the treatment of multiple myeloma, particularly in patients who have relapsed or become resistant to other therapies. It works by modulating the immune system to enhance the body’s ability to fight cancer cells. Pomalidomide inhibits tumor growth, induces apoptosis, and suppresses angiogenesis. It is also used in the treatment of certain types of myelodysplastic syndromes. Its mechanism of action includes activating T-cells and inhibiting pro-inflammatory cytokines.

Overview of Clinical Research

Pomalidomide is an angiogenesis inhibitor and an immunomodulator developed by Celgene Corporation. Amgen initiates phase II select trial for multiple myeloma therapy in USA, Spain, Denmark, Greece, Italy and Germany.